Health Condition 1: null- Acute Lymphoblastic Leukemia (ALL)
Conditions
Interventions
Intervention1: Mercaptopurine 50 mg tablet, Orion Pharma: A single oral dose (multiples of 50 mg) will be administered as per randomization schedule in each period with approximately 240 mL of water a
Sponsors
Orion Pharma
Eligibility
Inclusion criteria
Inclusion criteria: The patients who qualify for the study should meet all of the following inclusion criteria. 1. Adult patients, either sex, aged between 18 ? 75 years (both inclusive). 2. Patients of acute lymphoblastic leukemia (ALL) on maintenance therapy with once daily oral 6-MP and once weekly methotrexate, and the additional drugs (for example Daunorubicin, Doxorubicin, L-asparaginase, Vincristine, Methotrexate and Steroids) as per institutional or hospital?s guidelines. 3. BMI between 18.5 kg/m2 ? 30 kg/ m2 both inclusive. 4. Patients Screening clinical laboratory results are within clinically acceptable range 5. Patients are willing and able to adhere to the study visit schedule and other protocol requirements as evidenced by signed written informed consent. 6. Women of child-bearing potential and all men must agree to use a medically accepted method of contraception prior to screening, while receiving protocol-specified medication, and for 6 months after stopping the medication. Acceptable methods of contraception include hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm), intrauterine device (IUD), and abstinence (no sex). Women of child-bearing potential who are not currently sexually active must agree to use a medically accepted method of contraception while participating in the study; 7. Female patients of child-bearing potential must have a negative serum pregnancy test (beta-HCG) at screening and urine pregnancy test at the time of enrollment.
Exclusion criteria
Exclusion criteria: The patients meeting with any of the following criteria should be excluded: 1. Adult patients with ALL on maintenance therapy with olsalazine, mesalazine, or sulphasalazine, warfarin, allopurinol, thioguanine, and drugs whose primary or secondary toxicity is myelosuppression (for example trimethoprim-sulfamethoxazole). 2. Patients with inherited deficiency of the TPMT enzyme. 3. Pregnancy, expected pregnancy or lactation within 6 months. 4. Patients who have a history of a known allergy/sensitivity to study drug or its excipients; 5. Patients who have current signs and symptoms of systemic lupus erythematosus, or severe, progressive, or uncontrolled renal, hepatic, hematologic(other than ALL), endocrine, pulmonary, cardiac, neurologic, or cerebral diseases; 6. Patients who have poor tolerability of venipuncture or lack of adequate venous access for required blood sampling during the study period; 7. Patients who have had a known substance abuse or dependency (drug or alcohol) within 3 years of screening; 8. Patients who are participating in any other clinical study or who have received treatment with any investigational drug or device within 1month prior screening; Note: If the patient has participated in a study in which blood loss is more than 200 mL, patient can be dosed only after completion of 60 days from the previous study. 9. Patient who is part of the staff or a family member of the staff personnel directly involved with this study. 10. Any other condition that, in the investigator?s judgment, might increase the risk to the patient or decrease the chance of obtaining satisfactory information needed to achieve the objectives of the study. 11. Abnormal baseline findings considered by the investigator to indicate conditions that might affect study endpoints. 12. Patients who have a known infection with human immunodeficiency virus (HIV) and/or hepatitis B or hepatitis C.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To characterize the pharmacokinetic profile of test formulation relative to that of the reference and to assess their bioequivalence.Timepoint: Multiple time points up to 8 hours in each period | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the safety and tolerability of the two formulationsTimepoint: Through out the study period | — |
Countries
India
Contacts
Public ContactMr Prasann Bavania
NIL
Outcome results
None listed